Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis
    Meeting Abstract

    Rampal, R.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3
    Meeting Abstract

    Oluwole, O. O.; Ghobadi, A.; Cassaday, R. D.; Park, J. H.; Houot, R.; Logan, A.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC
    Meeting Abstract

    Deininger, M.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J. K.; Maness, L. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study
    Meeting Abstract

    Jabbour, E.; Tholouli, E.; Sandhu, K. S.; Shaughnessy, P.; Barba, P.; Guerreiro, M.; Yallop, D.; Logan, A.; Abedi, M.; Lao-Sirieix, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Khawaja, Mrruh; Naqash, A. R.; Schneider, R.; Shastri, A.; Stahl, M.; Moser, J. C.; Karim, N. F. A.; Madanat, Y.; Jonas, B. A.; Stein, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify)
    Meeting Abstract

    Daver, N. G.; Maiti, A.; Sallman, D. A.; Roboz, G. J.; Solh, M. M.; Milano, F.; Strickland, S. A.; Eghtedar, A.; Kanner, S. B.; Ledergor, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis
    Meeting Abstract

    Mascarenhas, J.; Maher, K. R.; Rampal, R.; Bose, P.; Podoltsev, N. A.; Hong, J.; Wang, X.; Kye, S.; Harrison, C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naive myelofibrosis and moderate thrombocytopenia
    Meeting Abstract

    Scandura, J.; Gerds, A. T.; Ritchie, E. K.; Wang, X. L.; Kye, S.; Rampal, R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib in the United States
    Meeting Abstract

    Marrone, M.; Geller, R.; Oladapo, A.; Suthar, P.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Rampal, R.; Mascarenhas, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real world incidence, prevention, and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax in the inpatient and outpatient settings
    Meeting Abstract

    Valtis, Y.; Nemirovsky, D.; Derkach, A.; Roeker, L. E.; Sharan, S.; Kabel, C.; Ortiz, R.; Geyer, M. B.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save